These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6300650)

  • 61. Inhibition by cyclopropane of release od norepinephrine, but not dopamine-beta-hydroxylase, from the guinea-pig vas deferens.
    Roizen MF; Thoa NB; Moss J; Kopin IJ
    Anesthesiology; 1976 Jan; 44(1):54-6. PubMed ID: 1244775
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A study of long-term effects of guanethidine on peripheral noradrenergic neurones of the rat.
    Bittiger H; Maĭtre L; Krinke G; Schnider K; Hess R
    Toxicology; 1977 Aug; 8(1):63-78. PubMed ID: 929619
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Normal calcium-activated potassium channel in red cells in type 2 diabetes.
    Burnett MA; Del Vecchio M; Bown E; O'Rahilly S; Turner RC
    Diabetes Res; 1987 May; 5(1):19-21. PubMed ID: 2441919
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Michaelis-Menten kinetics of calcium dependence of sympathetic neurotransmitter secretion in guinea-pig vas deferens: comparison between effects of phentolamine and of tetraethylammonium.
    Stjärne L
    Acta Physiol Scand; 1973 Sep; 89(1):142-4. PubMed ID: 4796882
    [No Abstract]   [Full Text] [Related]  

  • 65. [Pharmacological studies on guanethidine derivatives. VI. Effect of 2,3,4,5-tetrahydro-1H-2-benzazepine-2-carboxamidine sulfate on sympathomimetic amines].
    Ozawa H; Otsuki I
    Yakugaku Zasshi; 1967 Dec; 87(12):1553-5. PubMed ID: 5628369
    [No Abstract]   [Full Text] [Related]  

  • 66. Calcium-activated potassium channels in liver cells.
    Jenkinson DH; Haylett DG; Cook NS
    Cell Calcium; 1983 Dec; 4(5-6):429-37. PubMed ID: 6323005
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Apamin as a selective blocker of the calcium-dependent potassium channel in neuroblastoma cells: voltage-clamp and biochemical characterization of the toxin receptor.
    Hugues M; Romey G; Duval D; Vincent JP; Lazdunski M
    Proc Natl Acad Sci U S A; 1982 Feb; 79(4):1308-12. PubMed ID: 6122211
    [TBL] [Abstract][Full Text] [Related]  

  • 68. In vitro interactions of the new anorexic agent WY-5244 with cardiac and vascular tissue and with adrenergic mechanisms.
    Baum T; Gluckman MI
    J Pharmacol Exp Ther; 1967 Dec; 158(3):510-8. PubMed ID: 5624080
    [No Abstract]   [Full Text] [Related]  

  • 69. Steric aspects of adrenergic drugs. XX. Accumulation of (-)- and (+)-norepinephrine- 14 C by peripheral tissues of the rat.
    Krell RD; Patil PN
    J Pharmacol Exp Ther; 1972 Aug; 182(2):273-83. PubMed ID: 5048364
    [No Abstract]   [Full Text] [Related]  

  • 70. Conformational analogues of antihypertensive agents related to guanethidine.
    Borne RF; Forrester ML; Waters IW
    J Med Chem; 1977 Jun; 20(6):771-6. PubMed ID: 69025
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The effect of reserpine treatment and decentralization on the ion distribution in the vas deferens of the guinea-pig.
    Westfall DP
    Br J Pharmacol; 1970 May; 39(1):121-7. PubMed ID: 5420091
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Proceedings: Modulation of frequency-dependent noradrenaline release by calcium, angiotensin and morphine.
    Henderson G; Hughes J
    Br J Pharmacol; 1974 Nov; 52(3):455P-456P. PubMed ID: 4376440
    [No Abstract]   [Full Text] [Related]  

  • 73. Effects of calcium-removal and sodium-potassium adenosine triphosphatase inhibition on the release of epinephrine from the extraneuronal site.
    Katsuragi T; Suzuki T
    Life Sci; 1977 Jul; 21(1):137-44. PubMed ID: 18643
    [No Abstract]   [Full Text] [Related]  

  • 74. Comparative pharmacological studies on butriptyline and some related standard tricyclic antidepressants.
    Jaramillo J; Greenberg R
    Can J Physiol Pharmacol; 1975 Feb; 53(1):104-12. PubMed ID: 166748
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Factors affecting the action of guanethidine on adrenergic neurones.
    Gulati OD; Jaykar S
    Br J Pharmacol; 1971 Jul; 42(3):352-63. PubMed ID: 5560897
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The adrenergic neuron blocking activity of propranolol and alprenolol.
    Del Río J; López De Ceballos M
    Arch Farmacol Toxicol; 1975 Aug; 1(2):125-36. PubMed ID: 1230027
    [No Abstract]   [Full Text] [Related]  

  • 77. High affinity binding of [125I]monoiodoapamin to isolated guinea-pig hepatocytes.
    Cook NS; Haylett DG; Strong PN
    FEBS Lett; 1983 Feb; 152(2):265-9. PubMed ID: 6298001
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Chronic guanethidine treatment of female rats including effects on the fetus.
    Evans BK; Burnstock G
    J Reprod Fertil; 1979 Jul; 56(2):715-24. PubMed ID: 480323
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Acceleration of the rate limiting step in norepinephrine biosynthesis by potassium.
    Roth RH; Boadle M; Hughes J
    Experientia; 1970 May; 26(5):494-5. PubMed ID: 5462856
    [No Abstract]   [Full Text] [Related]  

  • 80. The release of guanethidine and bethanidine by splenic nerve stimulation: a quantitative evaluation showing dissociation from adrenergic blockade.
    Shand DG; Morgan DH; Oates JA
    J Pharmacol Exp Ther; 1973 Jan; 184(1):73-80. PubMed ID: 4686017
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.